SPOP and prostate carcinoma: These data indicate that patient-associated SPOP mutants lost the capacity to promote ubiquitination and destruction of HnRNPK, therefore partially providing a molecular mechanism to explain the aberrant accumulation of HnRNPK in prostate cancer cells and tissue.